SCHEMBL17375995

SCHEMBL17375995

N#Cc1ccc(-c2cn(CC3CCOC3)c(=O)c(N3CCC(N)CC3)n2)cc1F

nearest known ligand 0.72

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 17/20 0.72
EGLN2 Q96KS0 1/20 0.42
MTOR P42345 1/20 0.41
KCNH2 Q12809 1/20 0.39
SSTR5 P35346 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17375981 0.95 KDM1A (0.75) KDM1AKCNH2SSTR5
SCHEMBL17375939 0.90 KDM1A (0.81) KDM1AKCNH2
SCHEMBL17375972 0.84 KDM1A (1.00) KDM1AKCNH2
SCHEMBL17375985 0.79 KDM1A (1.00) KDM1A
SCHEMBL22031458 0.74 KDM1A (0.81) KDM1A
SCHEMBL17380946 0.74 KDM1A (0.81) KDM1A
SCHEMBL17222704 0.71 KDM1A (1.00) KDM1AKCNH2
SCHEMBL17222695 0.69 KDM1A (1.00) KDM1AKCNH2
SCHEMBL17375943 0.69 KDM1A (0.61) KDM1A
SCHEMBL17222691 0.68 KDM1A (1.00) KDM1AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106660987-B Inhibitors of lysine-specific demethylase-1 赛尔基因昆蒂赛尔研究公司 2020-11-06 CN claimed
EP-3160956-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2020-05-27 EP claimed
US-10597376-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-03-24 US claimed
US-20180273505-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2018-09-27 US claimed
US-11028066-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2021-06-08 US disclosed
US-11028066-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2021-06-08 US disclosed
CN-106660987-B Inhibitors of lysine-specific demethylase-1 赛尔基因昆蒂赛尔研究公司 2020-11-06 CN disclosed
US-20200172506-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-06-04 US disclosed
US-20200172506-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-06-04 US disclosed
EP-3160956-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2020-05-27 EP disclosed
US-10597376-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-03-24 US disclosed
US-10597376-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-03-24 US disclosed
US-20180273505-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2018-09-27 US disclosed
US-10011583-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-03 US disclosed
US-10011583-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-03 US disclosed
US-20170137402-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Quanticel Pharmaceuticals, Inc. 2017-05-18 US disclosed
US-20170137402-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Quanticel Pharmaceuticals, Inc. 2017-05-18 US disclosed
EP-3160956-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Celgene Quanticel Research, Inc. (US) 2017-05-03 EP disclosed
WO-2015200843-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Quanticel Pharmaceuticals, Inc. (US) 2015-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597376-B2 Inhibitors of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885EGLN2 239/4885MTOR 3219/4885
US-11028066-B2 Inhibitors of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885EGLN2 239/4885MTOR 3219/4885
US-20170137402-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885EGLN2 252/4885MTOR 2859/4885
US-20200172506-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885EGLN2 239/4885MTOR 3219/4885
US-10011583-B2 Inhibitors of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885EGLN2 239/4885MTOR 3219/4885
US-20180273505-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885EGLN2 239/4885MTOR 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.